Open AccessEuropean Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses
Author(s) -
Ludwig Heinz,
AvetLoiseau Hervé,
Bladé Joan,
Boccadoro Mario,
Cavenagh Jamie,
Cavo Michele,
Davies Faith,
Rubia Javier,
Delimpasi Sosana,
Dimopoulos Meletios,
Drach Johannes,
Einsele Hermann,
Facon Thierry,
Goldschmidt Hartmut,
Hess Urs,
Mellqvist UlfHenrik,
Moreau Philippe,
SanMiguel Jesús,
Sondergeld Pia,
Sonneveld Pieter,
Udvardy Miklos,
Palumbo Antonio
Publication year - 2012
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0391
Subject(s) - medicine , multiple myeloma , perspective (graphical) , intensive care medicine , medline , artificial intelligence , computer science , political science , law
The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies.